Vivesto — Capital/Financing Update 2014

Mar 25, 2014

2014-03-25

PRESS RELEASE

Oasmia receives a new MSEK 40 bank loan

Oasmia Pharmaceutical AB (publ) announced today that in accordance with its financial plan, the company has received a new MSEK 40 bank loan, with a term from April 1 to August 31, 2014. The loan replaces a previous bank loan which is due on March 31, 2014.

On March 7, 2014, Oasmia completed a private placement which, according to plan, provided the company with MSEK 68 after issue expenses.

€We now have the freedom of action to continue working with our prioritized projects•, says Oasmia CEO Julian Aleksov.

For more information, please contact: Mikael Widell, Vice President Communications Mobile: +46 70 311 99 60 E-mail: mikael.widell@oasmia.com

Notes to editors:

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

Information is also available at twitter.com/oasmia

€Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 14.20, CET on March 25, 2014.•